Repaglinide/Metformin Hydrochloride

็‘žๆ ผๅˆ—ๅฅˆ/็›้…ธไบŒ็”ฒๅŒ่ƒ

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRepaglinide/Metformin Hydrochloride
Drug Alias Name็‘žๆ ผๅˆ—ๅฅˆๅ’Œ็›้…ธไบŒ็”ฒๅŒ่ƒRepaglinide/Metformin็‘žๆ ผๅˆ—ๅฅˆ/ไบŒ็”ฒๅŒ่ƒRepaglinide and Metformin HydrochlorideMetformin Hydrochloride and Repaglinide +[9]ย 
ClassificationSmall molecules
Mechanisms of ActionPotassium channel blockersProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsVoltage-gated potassium channel blockers
TargetsPotassium channelVoltage-gated potassium channelProtein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2008/06/23
Country/TerritoryUnited StatesPuerto RicoMainland China
CombinationsYes Metformin HydrochlorideRepaglinide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesRecipharm Stockholm Ab
Inactive CompaniesNovo Nordisk IncNovo Nordisk A/S
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsDiabetes Mellitus

Other Information

ATC CodeA10BD14
Related LinksKEGG